Letters to the Editor

Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials

Hematology Unit and Biotechnology Research Unit, Azienda Ospedaliera of Cosenza, Cosenza,
Hematology Section, University of Bari
Department of Hematology, Businco Hospital, Cagliari
Hematology and Bone Marrow Transplant Unit, Ospedale Papa Giovanni XXIII, Bergamo
Hematology Unit and Biotechnology Research Unit, Azienda Ospedaliera of Cosenza, Cosenza
Hematology Unit, Ospedale Cardarelli, Napoli,
Dept of medica and surgical specialties, Hematology Section, University of Catania, Catania
Onco-hematology Unit, Ospedale Umberto I, Nocera Inferiore,
Hematology Unit, Parma University Hospital,
Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia
UOC Ematologia a Indirizzo Oncologico, AORN, Caserta;
Onco-hematology Unit Azienda Ospedaliera Santa Maria of Terni, Italy;
Internal Medicine, Ospedale S. Croce, Ospedali Riuniti Marche Nord, Fano
Ematologia, Università Cattolica, Fondazione Policlinico Gemelli IRCCS, Roma,
Hematology Unit, Careggi Hospital, Florence
Department of Biomedical Science, University of Bari;
Medicine, Hematology and Clinical Immunology, Padua University School of Medicine, Padua,
Hematology Unit, UOC Lecce,
Hematology Unit, Antonio Perrino Hospital, Brindisi,
Hematology and Bone Marrow Transplant Unit, Fondazione 'G. Pascale', IRCCS, Napoli
Hematology and Stem Cell Transplantation, IRCCS-CROB, Rionero in Vulture,
Department of Hematology, Hospital University Riuniti, Foggia
Hematology and Bone Marrow Transplant, Casa Sollievo della Sofferenza, San Giovanni Rotondo,
Hematology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola (MO)
Hematology Unit, A.O. Spedali Civili, Brescia,
Hematology Unit, AO S.G. Moscati, Aversa,
Hematology Department, G. Garibaldi Hospital, Catania,
Hematology Section, University of Bari
Hematology Unit and Biotechnology Research Unit, Azienda Ospedaliera of Cosenza, Cosenza
Hematology Unit and Biotechnology Research Unit, Azienda Ospedaliera of Cosenza, Cosenza
Hematology Unit, Great Metropolitan Hospital;
Section of Hematology, Department of Medicine, University of Verona, Verona,
Hematology Unit and Pathology Department, S. Eugenio Hospital Rome, Rome,
Hematology, DISM, University of Udine,
Hemato-Oncology and Radiotherapy, Great Metropolitan Hospital;
##plugins.themes.healthSciences.article.authorBio##
Hematology, Ospedale Santa Maria della Misericordia, University of Perugia, Perugia,
Hematology Unit, Fabrizio Spaziani Hospital, Frosinone,
Complex Operative Unit of Hematology, S. Maria di Loreto Nuovo Hospital, Napoli,
Hematology Unit, AUSL-IRCCS, Reggio Emilia,
Hematology Unit, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milano,
Biotechnology Research Unit, Azienda Ospedaliera of Cosenza, Cosenza,
Nephrology Center of National Research Institute, Reggio Calabria
CNR-IFC, Roma,
UOC Ematologia a Indirizzo Oncologico, AORN, Caserta;
Hematology Department, G. Garibaldi Hospital, Catania,
Div of Hematology,University of Torino,AOU Città della Salute e della Scienza di Torino,
Seragnoli Institute of Hematology and Medical Oncology, University of Bologna, Bologna,
Hematology, DISM, University of Udine,
Istituto di Ematologia, Università Cattolica, Fondazione Policlinico Gemelli IRCCS, Roma,
Department of Medical and Surgical Specialties, Hematology Section, University of Catania
Hematology Unit, Ospedale Cardarelli, Napoli
Department of Cellular Biotechnologies and Hematology, Sapienza University of Rome
Hematology Unit, AOU Ospedali Riuniti di Ancona,
Div of Hematology,University of Torino,AOU Città della Salute e della Scienza di Torino
Seragnoli Institute of Hematology and Medical Oncology, University of Bologna, Bologna
Hemato-Oncology Department, Augusta Victoria Hospital of Jerusalem,
Vol. 106 No. 1 (2021): January, 2021 https://doi.org/10.3324/haematol.2019.241513